Suven Life Sciences secures product patents in Norway, S Korea and Singapore

Suven Life Sciences secured product patents from Norway, South Korea and Singapore regulators corresponding to the New Chemical Entities (NCEs) for the treatment of disorders allied with Neurodegenerative diseases.

The approval of these grants is for the pipeline of molecules in CNS (Central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally.

Suven Life Science is mainly engaged into discovering, developing and commercializing novel pharmaceutical products.

On Thursday, the stock opened at Rs. 170.70 per share and touched an intra-day high of Rs. 175, cheering the announcement.